[go: up one dir, main page]

WO2004071425A3 - The combined use of cruciferous indoles and chelators for the treatment of papillomavirus-related conditions - Google Patents

The combined use of cruciferous indoles and chelators for the treatment of papillomavirus-related conditions Download PDF

Info

Publication number
WO2004071425A3
WO2004071425A3 PCT/US2004/003392 US2004003392W WO2004071425A3 WO 2004071425 A3 WO2004071425 A3 WO 2004071425A3 US 2004003392 W US2004003392 W US 2004003392W WO 2004071425 A3 WO2004071425 A3 WO 2004071425A3
Authority
WO
WIPO (PCT)
Prior art keywords
papillomavirus
treatment
chelators
related conditions
combined use
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/003392
Other languages
French (fr)
Other versions
WO2004071425A2 (en
Inventor
Michael A Zeligs
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BioResponse LLC
Original Assignee
BioResponse LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BioResponse LLC filed Critical BioResponse LLC
Priority to AU2004211931A priority Critical patent/AU2004211931A1/en
Priority to EP04708975A priority patent/EP1601367A2/en
Priority to CA002515424A priority patent/CA2515424A1/en
Publication of WO2004071425A2 publication Critical patent/WO2004071425A2/en
Publication of WO2004071425A3 publication Critical patent/WO2004071425A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Synergistic compositions and methods are disclosed for using cruciferous indoles with iron/zinc chelators in the treatment of papillomavirus-related conditions. These synergistic compositions of diindolylymethane (DIM), related trimeric derivatives, and related indole derivatives include combinations with deferoxamine, deferiprone, bipyridyl, Desferri-exochelin, picolinic acid, 3-hydroxypicolinic acid, and sodium butyrate as iron/zinc chelators. The methods described comprise more effective therapies for common cutaneous warts (verrucae) and related dysplasias of the oropharynx, genitalia, and uterine cervix.
PCT/US2004/003392 2003-02-06 2004-02-06 The combined use of cruciferous indoles and chelators for the treatment of papillomavirus-related conditions Ceased WO2004071425A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2004211931A AU2004211931A1 (en) 2003-02-06 2004-02-06 The combined use of cruciferous indoles and chelators for the treatment of papillomavirus-related conditions
EP04708975A EP1601367A2 (en) 2003-02-06 2004-02-06 The combined use of cruciferous indoles and chelators for the treatment of papillomavirus-related conditions
CA002515424A CA2515424A1 (en) 2003-02-06 2004-02-06 The combined use of cruciferous indoles and chelators for the treatment of papillomavirus-related conditions

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US44591603P 2003-02-06 2003-02-06
US44588803P 2003-02-06 2003-02-06
US60/445,916 2003-02-06
US60/445,888 2003-02-06

Publications (2)

Publication Number Publication Date
WO2004071425A2 WO2004071425A2 (en) 2004-08-26
WO2004071425A3 true WO2004071425A3 (en) 2005-02-03

Family

ID=32871963

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/003392 Ceased WO2004071425A2 (en) 2003-02-06 2004-02-06 The combined use of cruciferous indoles and chelators for the treatment of papillomavirus-related conditions

Country Status (5)

Country Link
US (2) US20040225004A1 (en)
EP (1) EP1601367A2 (en)
AU (1) AU2004211931A1 (en)
CA (1) CA2515424A1 (en)
WO (1) WO2004071425A2 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005051388A1 (en) * 2003-11-21 2005-06-09 Novactyl Incorporated Compositions and methods useful for treatment of conjunctivitis
EP1838303B1 (en) * 2004-12-30 2011-02-09 Bioresponse LLC Use of diindolylmethane-related indoles for the treatment and prevention of respiratory syncytial virus associates conditions
CA2619568A1 (en) * 2005-08-19 2007-03-01 Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services Topical formulations of histone deacetylase inhibitors and methods of using the same
AU2006287175A1 (en) * 2005-09-01 2007-03-08 Precision Therapeutics, Inc. Chemo-sensitivity assays using tumor cells exhibiting persistent phenotypic characteristics
JP5264494B2 (en) * 2005-11-01 2013-08-14 マウント シナイ スクール オブ メディスン Growth control of oral and superficial microorganisms using gallium compounds
BRPI0711385A2 (en) * 2006-05-09 2011-11-08 Novartis Ag combination comprising an iron chelator and an antineoplastic agent and its use
JP5600004B2 (en) * 2006-09-05 2014-10-01 エモリー ユニバーシティー Tyrosine kinase inhibitors for the prevention or treatment of infection
ITMI20061770A1 (en) * 2006-09-18 2008-03-19 Carlo Ghisalberti COSMETIC METHOD OF REDUCING EYES
BRPI0717753B1 (en) 2006-10-27 2022-04-12 Bioresponse, Llc Use of a composition comprising 50-250 mg of one or more dim-related indoles and one or more anti-protozoal agents, and, composition
US20100292209A1 (en) * 2007-03-30 2010-11-18 Massachusetts Institute Of Technology Methods for identifying compounds that modulate neurotrophic factor signaling
US20090068190A1 (en) * 2007-08-29 2009-03-12 Drugtech Corporation Anti-proliferative combinations
US8178134B2 (en) * 2008-01-03 2012-05-15 Delhi Institute of Pharmaceuticals and Research Synergistic herbal ophthalmic formulation for lowering intraocular pressure in case of glaucoma
JP5468015B2 (en) 2008-01-08 2014-04-09 アクセリア ファーマシューティカルズ Agonists for antimicrobial peptide systems
KR20120078667A (en) * 2009-01-26 2012-07-10 마이클 스피노 Use of deferiprone for treatment and prevention of iron-related eye disorders
US20120245135A1 (en) * 2011-03-24 2012-09-27 Genta Incorporated Gallium Complexes, Pharmaceutical Compositions And Methods Of Use
KR101301253B1 (en) * 2011-12-09 2013-08-28 한국원자력연구원 Preparation method of chromenone derivatives using the radiation
US9375001B1 (en) 2012-04-23 2016-06-28 Wellmark International Granular fly bait
GB201317619D0 (en) 2013-10-04 2013-11-20 Uni I Oslo Compounds
CN103599093B (en) * 2013-11-18 2016-06-01 中国医学科学院生物医学工程研究所 A kind of anti-HPV pharmaceutical preparation and purposes
US11807896B2 (en) * 2015-03-26 2023-11-07 Dovetail Genomics, Llc Physical linkage preservation in DNA storage
US9918965B2 (en) 2015-04-10 2018-03-20 Bioresponse, L.L.C. Self-emulsifying formulations of DIM-related indoles
EP3195854A1 (en) 2016-01-22 2017-07-26 Tomorrowlabs GmbH Cosmetic treatment of healthy skin, in particular aged skin
EP3954771B1 (en) 2016-05-13 2025-09-03 Dovetail Genomics, LLC Recovering long-range linkage information from preserved samples
GB201613946D0 (en) 2016-08-15 2016-09-28 Univ Oslo Compounds
AU2018255269B2 (en) 2017-04-17 2023-03-09 The University Of Chicago Polymer materials for delivery of short-chain fatty acids to the intestine for applications in human health and treatment of disease
US11253480B2 (en) * 2017-10-30 2022-02-22 University of Pittsburgh—of the Commonwealth System of Higher Education Treatment of ocular conditions utilizing a histone/protein deacetylase inhibitor
US20210023023A1 (en) * 2019-07-25 2021-01-28 Vasayo, Llc Liposomal nutraceutical compositions and methods of making the same
US12064467B2 (en) * 2022-10-28 2024-08-20 Transdermal Biotechnology, Inc. Systems and methods for delivery of humanin or other peptides
GB202306833D0 (en) 2023-05-09 2023-06-21 Adjutec Pharma As Therapy
GB202306835D0 (en) 2023-05-09 2023-06-21 Adjutec Pharma As Therapy
GB202306826D0 (en) 2023-05-09 2023-06-21 Adjutec Pharma As Therapy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001024799A1 (en) * 1999-10-04 2001-04-12 Bernstein Lawrence R Gallium complexes of 3-hydroxy-4-pyrones to treat infection by intracellular prokaryotes, dna viruses and retroviruses
US6399645B1 (en) * 2000-03-20 2002-06-04 Maria Bell Chemoprevention and treatment of cervical or vaginal neoplasia
US20030096855A1 (en) * 2001-10-23 2003-05-22 Zeligs Michael A. Diindolylmethane for the treatment of HPV infection

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001024799A1 (en) * 1999-10-04 2001-04-12 Bernstein Lawrence R Gallium complexes of 3-hydroxy-4-pyrones to treat infection by intracellular prokaryotes, dna viruses and retroviruses
US6399645B1 (en) * 2000-03-20 2002-06-04 Maria Bell Chemoprevention and treatment of cervical or vaginal neoplasia
US20030096855A1 (en) * 2001-10-23 2003-05-22 Zeligs Michael A. Diindolylmethane for the treatment of HPV infection

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SIMONART ET AL: "Antiproliferative and apoptotic effects of iron chelators on human cervical carcinoma cells", GYNECOLOGIC ONCOLOGY, vol. 85, 2002, pages 95 - 102, XP002236573 *

Also Published As

Publication number Publication date
US20050063903A1 (en) 2005-03-24
WO2004071425A2 (en) 2004-08-26
AU2004211931A1 (en) 2004-08-26
CA2515424A1 (en) 2004-08-26
US20040225004A1 (en) 2004-11-11
EP1601367A2 (en) 2005-12-07

Similar Documents

Publication Publication Date Title
WO2004071425A3 (en) The combined use of cruciferous indoles and chelators for the treatment of papillomavirus-related conditions
WO2006121518A3 (en) Electrical devices, anti-scarring agents, and therapeutic compositions
WO2001060814A3 (en) Pyrrole substituted 2-indolinone protein kinase inhibitors
AU2003217277A1 (en) Indole, azaindole and related heterocyclic pyrrolidine derivatives
IL146491A0 (en) APo-2L RECEPTOR AGONIST AND CPT-11 SYNERGISM
WO2007073505A3 (en) Trpa1 inhibitors for treating pain
WO2006116353A3 (en) N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions associated with oxidative stress
WO2006040688A3 (en) Inhibitors of acetylcholinesterase for treating skin diseases
JO2356B1 (en) N-biphenyl(substituted methyl) aminocycloalkanecarboxamide derivatives
CY1110664T1 (en) INTENSIVE COMPOSITION
WO2005004808A3 (en) TETRACYCLIC COMPOUNDS AS c-MET INHIBITORS
IL166371A0 (en) Benzimidazole derivatives and their use as prodrugs of proton pump inhibitor
AU2002366583A1 (en) Electrostimulation device for users of means of transport
GB0308952D0 (en) Method
WO2007109290A3 (en) Water-soluble zinc ionophores, zinc chelators, and/or zinc complexes and use for treating cancer
WO2005077365A3 (en) Novel uses for proton pump inhibitors
AU4651700A (en) Salts of aminoimidazole carboxamide useful in the prevention and treatment of liver diseases
WO2002080854A3 (en) Compositions and methods for the prevention and treatment of human prostate cancer
TW200612967A (en) Anti-viral uses of borinic acid complexes
MXPA05006526A (en) Treatment of mastalgia with 4-hydroxy tamoxifen.
IS5570A (en) Treatment of giant lupus erythematosus with the adenocytes
AU2003258630A1 (en) Pyrimidine derivatives as selective cox-2 inhibitors
EP1046397A3 (en) Novel bioactivating substance
IL141232A0 (en) Use of camptothecin derivatives, with reduced gastrointestinal toxicity
WO2006063164A3 (en) Compositions and methods for treating neuroendocrine tumors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2515424

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004211931

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 542128

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2004211931

Country of ref document: AU

Date of ref document: 20040206

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004211931

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004708975

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004708975

Country of ref document: EP